Efgartigimod alfa fcab brand name?

What is the brand name for Efgartigimod alfa fcab?

Efgartigimod alfa fcab is a recombinant IgG1κ monoclonal antibody directed against the neonatal Fc receptor (FcRn) [1]. It is a novel therapeutic agent in clinical development for various autoimmune diseases, including myasthenia gravis, myositis, and lupus.

Why is it worth noting for autoimmunity?

Efgartigimod alfa fcab targets the FcRn, a receptor responsible for salvaging and recycling IgG antibodies from the catabolism pathway. By blocking this receptor, Efgartigimod alfa fcab increases the clearance of IgG antibodies, a potential therapeutic strategy for autoimmune diseases characterized by elevated levels of pathogenic IgG antibodies [2].

Is it worth watching patent activity for this drug?

Efgartigimod alfa fcab is developed by US WorldMeds and Liminal Therapeutics. There is considerable patent activity surrounding this drug, particularly in the area of FcRn-targeted therapies [3]. To stay informed about developments in this area, visit DrugPatentWatch.com [4].

Other developments in FcRn-targeted therapy

Other companies, like Neovacs and Kedrion, have also been exploring FcRn-targeted therapy approaches. These developments may compete with Efgartigimod alfa fcab for market share in the field of autoimmune disease treatment [5].

Timeline for patent expirations

Keep in mind that patent expirations can greatly impact the development and availability of treatments. Visit DrugPatentWatch.com to track updates on patent expirations and new market entrants [4].

References:

[1] Liminal Therapeutics. (2023). Efgartigimod alfa fcab - Development Program.

[2] Efgartigimod alfa fcab - NDA 210845. (2023).

[3] World Intellectual Property Organization. (2023).

[4] DrugPatentWatch.com.

[5] Neovacs. (2023). IFNα-Kappa (KEDRYNO).